Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613220536> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2613220536 endingPage "10025" @default.
- W2613220536 startingPage "10025" @default.
- W2613220536 abstract "10025 Background: Weekly vinblastine was evaluated in a phase II study in children with recurrent or refractory low grade gliomas. Methods: Vinblastine was given intravenously at a dose of 6 mg/m2 weekly for 52 weeks. Eligible patients were neurofibromatosis (NF1) or non NF1 patients < 18 year old who had previously failed chemotherapy and/or radiation for unresectable low grade glioma. Responses were assessed every 3 months during vinblastine administration. Results: The Study opened in 2003 and accrual was completed in 2006. 51 eligible pts (27 females, 24 males, median age 7.2 yrs, range 1.4 to 16.8) were enrolled on this study. 9 patients had NF1. Pathological diagnosis was pilocytic astrocytoma (29), Low grade astrocytoma NOS (9), ganglioglioma (2), pilomyxoid astrocytoma (1) and 10 patients were diagnosed on imaging only. 37 patients had received a previous line of chemotherapy, 11 two lines, 2 three lines and 9 had received previous radiation. 29 (57%) patients completed 52 weeks of chemotherapy. 3 discontinued vinblastine for toxicity (2 peripheral neuropathy, 1 recurrent rash). Main toxicity was hematological with 27 patients who required transient or permanent dose reduction. Progression during treatment (> 25% increase in 2D or > 40% in 3D tumor size) occurred in 20 patients, including one who eventually showed partial response following further vinblastine administration. Independent central radiology review on the 31 first patients reports 1 CR, 3 PR, 9 minor responses (MR), 10 stable disease and 10 progression, with an overall response rate (CR+PR+MR) of 42%. At a median follow-up of 31 months, 19 out of 29 patients who completed 52 weeks of therapy are progression free. Conclusions: This is the largest phase II chemotherapy study ever conducted in recurrent/refractory low grade glioma. This study shows that sustained responses can be achieved with weekly vinblastine used as second line chemotherapy. The low toxicity profile of this agent and the potential for extended administration (> 12 months) without significant cumulative toxicity makes this agent a potentially useful drug for the treatment of pediatric low grade gliomas. Supported by a grant from the Ontario Cancer Research Network (OCRN) No significant financial relationships to disclose." @default.
- W2613220536 created "2017-05-19" @default.
- W2613220536 creator A5001495758 @default.
- W2613220536 creator A5012407631 @default.
- W2613220536 creator A5012736355 @default.
- W2613220536 creator A5013529173 @default.
- W2613220536 creator A5029944513 @default.
- W2613220536 creator A5038794162 @default.
- W2613220536 creator A5057479866 @default.
- W2613220536 creator A5068257880 @default.
- W2613220536 creator A5089569857 @default.
- W2613220536 date "2008-05-20" @default.
- W2613220536 modified "2023-09-26" @default.
- W2613220536 title "Phase II study of weekly vinblastine in recurrent/refractory pediatric low grade gliomas" @default.
- W2613220536 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.10025" @default.
- W2613220536 hasPublicationYear "2008" @default.
- W2613220536 type Work @default.
- W2613220536 sameAs 2613220536 @default.
- W2613220536 citedByCount "3" @default.
- W2613220536 countsByYear W26132205362023 @default.
- W2613220536 crossrefType "journal-article" @default.
- W2613220536 hasAuthorship W2613220536A5001495758 @default.
- W2613220536 hasAuthorship W2613220536A5012407631 @default.
- W2613220536 hasAuthorship W2613220536A5012736355 @default.
- W2613220536 hasAuthorship W2613220536A5013529173 @default.
- W2613220536 hasAuthorship W2613220536A5029944513 @default.
- W2613220536 hasAuthorship W2613220536A5038794162 @default.
- W2613220536 hasAuthorship W2613220536A5057479866 @default.
- W2613220536 hasAuthorship W2613220536A5068257880 @default.
- W2613220536 hasAuthorship W2613220536A5089569857 @default.
- W2613220536 hasConcept C121332964 @default.
- W2613220536 hasConcept C126322002 @default.
- W2613220536 hasConcept C126838900 @default.
- W2613220536 hasConcept C141071460 @default.
- W2613220536 hasConcept C142424586 @default.
- W2613220536 hasConcept C2776694085 @default.
- W2613220536 hasConcept C2777132456 @default.
- W2613220536 hasConcept C2777722931 @default.
- W2613220536 hasConcept C2778227246 @default.
- W2613220536 hasConcept C2778880634 @default.
- W2613220536 hasConcept C2778984943 @default.
- W2613220536 hasConcept C502942594 @default.
- W2613220536 hasConcept C71924100 @default.
- W2613220536 hasConcept C87355193 @default.
- W2613220536 hasConcept C90924648 @default.
- W2613220536 hasConceptScore W2613220536C121332964 @default.
- W2613220536 hasConceptScore W2613220536C126322002 @default.
- W2613220536 hasConceptScore W2613220536C126838900 @default.
- W2613220536 hasConceptScore W2613220536C141071460 @default.
- W2613220536 hasConceptScore W2613220536C142424586 @default.
- W2613220536 hasConceptScore W2613220536C2776694085 @default.
- W2613220536 hasConceptScore W2613220536C2777132456 @default.
- W2613220536 hasConceptScore W2613220536C2777722931 @default.
- W2613220536 hasConceptScore W2613220536C2778227246 @default.
- W2613220536 hasConceptScore W2613220536C2778880634 @default.
- W2613220536 hasConceptScore W2613220536C2778984943 @default.
- W2613220536 hasConceptScore W2613220536C502942594 @default.
- W2613220536 hasConceptScore W2613220536C71924100 @default.
- W2613220536 hasConceptScore W2613220536C87355193 @default.
- W2613220536 hasConceptScore W2613220536C90924648 @default.
- W2613220536 hasIssue "15_suppl" @default.
- W2613220536 hasLocation W26132205361 @default.
- W2613220536 hasOpenAccess W2613220536 @default.
- W2613220536 hasPrimaryLocation W26132205361 @default.
- W2613220536 hasRelatedWork W1993528026 @default.
- W2613220536 hasRelatedWork W200051266 @default.
- W2613220536 hasRelatedWork W2022790460 @default.
- W2613220536 hasRelatedWork W2040064088 @default.
- W2613220536 hasRelatedWork W2066720664 @default.
- W2613220536 hasRelatedWork W2096804685 @default.
- W2613220536 hasRelatedWork W2548638278 @default.
- W2613220536 hasRelatedWork W2947767395 @default.
- W2613220536 hasRelatedWork W2949262565 @default.
- W2613220536 hasRelatedWork W4220817190 @default.
- W2613220536 hasVolume "26" @default.
- W2613220536 isParatext "false" @default.
- W2613220536 isRetracted "false" @default.
- W2613220536 magId "2613220536" @default.
- W2613220536 workType "article" @default.